埃托啡盐酸盐 | 13764-49-3

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 中文名称: 埃托啡盐酸盐
• 中文别名: 羟戊甲吗啡盐酸盐；盐酸埃托啡
• 英文名称: Etorphine Hydrochloride
• 英文别名: (1R,2S,6R,14R,15R,19R)-19-[(2R)-2-hydroxypentan-2-yl]-15-methoxy-5-methyl-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,16-tetraen-11-ol;hydrochloride
• CAS: 13764-49-3
• 化学式: C25H34ClNO4
• 分子量: 448.0
• InChiKey: JNHPUZURWFYYHW-DTUSRQQPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.59
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  62.2
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Non-Racemic Mixtures of Various Ratios of D- and L-methadone and Methods of Treating Pain Using the Same
  申请人：MIRONER Y. Eugene

  公开号：US20160235691A1

  公开（公告）日：2016-08-18

  Non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, such as for example about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or about 3:1 by weight of D-methadone to L-methadone, have been found to exhibit surprising and unexpected beneficial results in the treatment of neuropathic pain. Additionally, non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or for example about 3:1 by weight of D-methadone to L-methadone, in combination with other non-methadone opioids have been found to exhibit surprising and unexpected beneficial results in the treatment of mixed pain.

  非外消旋混合物的D-和L-美沙酮，其含有D-美沙酮与L-美沙酮按重量比大约为2.5:1至大约3.5:1，例如大约为2.9:1至大约3.1:1，或者大约为3:1，已被发现在神经痛的治疗中表现出令人惊讶和意想不到的益处。此外，非外消旋混合物的D-和L-美沙酮，其含有D-美沙酮与L-美沙酮按重量比大约为2.5:1至大约3.5:1，大约为2.9:1至大约3.1:1，或者例如大约为3:1，与其他非美沙酮类阿片类药物结合使用，已被发现在混合性疼痛的治疗中表现出令人惊讶和意想不到的益处。
• Purine compounds and methods of use thereof
  申请人：Salzman L. Andrew

  公开号：US20070238694A1

  公开（公告）日：2007-10-11

  The invention relates to Purine Compounds; compositions comprising an effective amount of a Purine Compound; and methods for reducing a subject's rate of metabolism or protecting a subject's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, diabetes, a cellular proliferative disorder, a skin disorder, a radiation-induced injury, a wound or an inflammatory disease comprising administering an effective amount of a Purine Compound to a subject in need thereof.

  这项发明涉及嘌呤化合物；包含有效量嘌呤化合物的组合物；以及用于减少受试者代谢率或在心脏停搏期间保护受试者心脏免受心肌损伤，或用于治疗或预防心血管疾病、神经系统紊乱、缺血情况、再灌注损伤、肥胖、消耗性疾病、糖尿病、细胞增殖紊乱、皮肤疾病、辐射诱导损伤、创伤或炎症疾病的方法，包括向需要的受试者施用有效量的嘌呤化合物。
• Dosage forms
  申请人：——

  公开号：US20030059397A1

  公开（公告）日：2003-03-27

  Solid oral dosage forms of controlled substances are described that have reduced potential for abuse by inhalation, mastication, and injection.

  描述了固体口服剂型的受控物质，其具有减少吸入、咀嚼和注射滥用的潜力。
• Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
  申请人：Jagtap Prakash

  公开号：US20050282768A1

  公开（公告）日：2005-12-22

  The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.

  本发明涉及嘌呤衍生物；包括有效量的嘌呤衍生物的组合物；以及用于减缓动物代谢率，保护动物心脏在心肌停搏期间免受心肌损伤的方法；或用于治疗或预防心血管疾病、神经系统疾病、缺血性疾病、再灌注损伤、肥胖症、消耗性疾病或糖尿病的方法，其中包括向需要的动物投与有效量的嘌呤衍生物。
• Pharmaceutical compositions for prevention of overdose or abuse
  申请人：Mickle Travis

  公开号：US20060014697A1

  公开（公告）日：2006-01-19

  The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.

  本发明涉及制药组合物，其中化学基团连接到活性剂上，以大大降低活性剂引起过量或被滥用的潜力。当以适当剂量给予时，该制药组合物提供与母体活性剂类似的治疗活性。